Abstract:Background/aims: In pediatric oncology, a Phase II trial often utilizes a safety run-in phase followed by an efficacy phase that enrolls at the dose level selected based on the safety run-in. Different from a Phase I trial, a Phase II safety run-in often assesses a very small number of dose levels. In the context of a safety run-in that assesses two or three dose levels, this article aims to compare three design methods, including the algorithm-based designs 3 + 3 and Rolling 6, and the model-assisted designs such as the Bayesian optimal interval design. Methods: Extensive simulations were conducted to evaluate and compare operating characteristics of the three design methods for a safety run-in with two or three dose levels, varying the starting dose level. Results: The performance of algorithm-based and model-assisted designs can be influenced by selection of the starting dose level, with trials starting at a lower dose level having a higher probability of selecting a low dose or considering all doses as toxic. The impact is larger for 3 + 3 and Rolling 6 but to a lesser extent for Bayesian optimal interval design. For a safety run-in with two dose levels, using 3 + 3 or Rolling 6 and starting at the higher dose often lead to similar performance to Bayesian optimal interval design. For safety run-in with three dose levels, starting at the middle dose with 3 + 3, Rolling 6 or Bayesian optimal interval design is a good compromise between improving correct dose selection and imposing a toxic dose to less patients. Conclusions: Despite being sensitive to the starting dose level, the 3 + 3, Rolling 6 and Bayesian optimal interval designs overall demonstrate reasonable performance, which can be further improved with wise selection of the starting dose level. The Rolling 6 design remains the recommended design method especially if pharmacokinetics is important or required with this design having the feature of treating six patients per dose level. When designing a safety run-in, selection of a design method or selection of a starting dose should consider both the performance of the design approaches with different choices of a starting dose level and the magnitude of safety concerns with the dose levels under investigation.

Design study of pharmacokinetics and comparison of 4 kinds of the clinal trial phase Ⅱ design of roxithromycin/ambroxol hydrochloride compound tablets

Study on bioequivalence of cilostazol table in healthy volunteers

Pharmacokinetic And Bioequivalence Study Of Three Oral Formulations Of Ambroxol 30 Mg: A Randomized, Three-Period Crossover Comparison In Healthy Volunteers

Study on the Design of Clinical Trial Protocol for New Drugs

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Pharmacokinetics and bioequivalence of roxithromycin capsules in healthy volunteers

Study on the key steps for the subject medication of phase Ⅰ clinical trials

General Considerations and of Protocol of Phase II Clinical Trial for Marketing Applications

Consideration on Phase Ⅰ Clinical Trial Design for Anticancer Drugs

BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.

Bayesian Optimal Interval Designs for Phase I Clinical Trials

Phase I–II Clinical Trial Design: a State-of-the-art Paradigm for Dose Finding

Pharmacokinetic-pharmacodynamic Analysis' Role in Design of Phase ROMAN NUMERAL ONE Clinical Trials of Anticoagulant Agents: a Systematic Review

Seamless Phase II/III Design: a Useful Strategy to Reduce the Sample Size for Dose Optimization

Analysis on Application Rationality of Ambroxol Tablets in 50210 Outpatient Prescriptions from Eye and ENT Hospital of Fudan University

Multi-stage Design in Phase Ⅱ Clinical Trials for Anti-Cancer Drug Development

Pharmacokinetics and Bioequivalance of Ambroxol Dispersible Tablets in Healthy Volunteers

Protocol Deviations in Clinical Trials of New Drug Application

Study on Bioequivalence of Ambroxol Hydrochloride Tablets from Domestic and Import

Comparison of design methods for a safety run-in phase of a phase II clinical trial

Early Stage Preclinical Formulation Strategies to Alter the Pharmacokinetic Profile of Two Small Molecule Therapeutics